ADHD in the News 2022-05-05

A clash over online Adderall prescriptions is raising new questions about telehealth

Online pharmacy startups have pledged to make it faster and easier than ever to get needed medications. But a high-profile series of setbacks is calling into question whether the realities of drug prescribing are clashing with those promises.

Adherence to ADHD Meds May Lower Unemployment Risk

Adherence to medication for attention-deficit/hyperactivity disorder (ADHD) is linked to a significantly lower the risk for unemployment, particularly among women, new research suggests.

Breaking Down the Stigma Surrounding ADHD

Imagine being unable to read a paragraph or follow a conversation without your mind wandering. Losing track of time is something you’re known for among family and friends, and you can’t seem to meet deadlines despite your best efforts. Your tendency to speak without thinking sometimes bruises feelings. You may occasionally interrupt people so you don’t forget what you want to say. Now imagine your friends and family telling you that attention deficit hyperactivity disorder (ADHD) isn’t a real condition, and you should just try harder.

Cerebral’s Preferred Pharmacy Truepill Halts Adderall Prescriptions for All Customers

Online pharmacy company Truepill Inc. said it is temporarily halting prescriptions for Adderall and other controlled substances used to treat attention-deficit hyperactivity disorder, and partner Cerebral Inc. told its clinicians to direct those orders to patients’ local pharmacies.

Mental Health Startup Cerebral To Stop ADHD Prescriptions For New Patients

The mental health startup Cerebral said it would stop prescribing controlled substances to treat ADHD for new patients on Wednesday, a week after an ex-executive filed a lawsuit alleging he was fired in retaliation for speaking up about unethical business practices, including the company’s practice of overprescribing stimulants in order to retain patients.

FDA OKs New Nonstimulant Option for Adult ADHD

The FDA expanded the approval of viloxazine extended-release capsules (Qelbree) to include adults with ADHD, Supernus Pharmaceuticals announced. Now indicated for adults ages 18 and older, viloxazine is the first nonstimulant ADHD option for adults in 20 years. The agent was initially approved in April 2021 for children ages of 6 to 17.

FDA Approves Xelstrym to Treat ADHD

Key takeaways: In March 2022, Xelstrym (dextroamphetamine) became the first FDA-approved amphetamine patch to treat ADHD in adults and children at least 6 years of age. Common side effects of Xelstrym include a smaller appetite, trouble sleeping, and headache. More serious side effects include dependence, heart problems, and serotonin syndrome. Xelstrym will probably be available in the second half of 2022. We don’t know how much it will cost yet.

Autism, ADHD and school absence are risk factors for self-harm, according to new study

Research led by King's College London and South London and Maudsley NHS Foundation Trust has analyzed factors associated with self-harm in over 111,000 adolescents aged 11-17 years old. Published in BMC Medicine the study found that the risk for self-harm presenting to hospital emergency departments was nearly three times higher for boys with autism spectrum disorder (ASD) compared to boys without ASD. Attention Deficit Hyperactivity Disorder (ADHD) was a strong predictor of self-harm for both boys and girls with approximately a four-fold increased risk for self-harm amongst those with ADHD.

Pitt research helps explain how Ritalin sharpens attention

Even half a century after a drug comes on the market, scientists can still learn new things about how it works. New research from University of Pittsburgh neuroscientists provides a rare look at how Ritalin affects activity in the brains of animals, providing a deeper understanding of how groups of brain cells govern attention and pointing to new possible uses for the stimulant.

‘Eye-Catching’ Smartphone App Could Make It Easy To Screen for Neurological Disease at Home

Researchers at the University of California San Diego have developed a smartphone app that could allow people to screen for Alzheimer’s disease, ADHD and other neurological diseases and disorders—by recording closeups of their eye.

Video games could help treat cognitive disorders like depression and ADHD

Researchers are turning to a unexpected treatment for cognitive disorders: video games.

All About ADHD Paralysis

When you’re overwhelmed by a million tasks and end up doing nothing — that’s what ADHD paralysis feels like.